ABNX ABIONYX Pharma SA

1.691USD1.542 EUR · EPA-1.03%Mkt Cap: 75.44M USDP/E: —

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activiti…

Key Statistics

Company
Market Cap75.44M USD
Enterprise Value61.09M USD
Revenue (TTM)4.46M USD
Gross Profit585.69K USD
Net Income (TTM)-6.09M USD
Revenue/Share0.13 USD
Last Price1.691 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees49
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012616852
Valuation
P/E (Trailing)—
P/E (Forward)-4.62
PEG—
EV/EBITDA-10.27
EV/Revenue13.71
P/S16.93
P/B12.27
EPS (TTM)-0.24 USD
EPS (Forward)-0.37 USD
52W Range
1.5514% of range4.826
52W High4.826 USD
52W Low1.551 USD
Profitability
Gross Margin13.14%
Oper. Margin-136.30%
EBITDA Margin-133.47%
Profit Margin-136.60%
ROE-123.01%
ROA-42.32%
ROIC-113.18%
ROCE-68.26%
Growth
Revenue Growth-11.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.22M USD
CapEx (TTM)265.43K USD
FCF Margin-7.07%
FCF Yield-0.42%
Net Debt311.49K USD
Net Debt/EBITDA-0.05
Net Debt/FCF—
Balance Sheet
Debt/Equity0.84
Current Ratio1.06
Quick Ratio0.99
Book Value/Sh0.14 USD
Cash/Share0.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)10.69 USD
Upside (mean)+532.3%
Target Range9.323 USD – 12.06 USD
9.323+532.3% to mean12.06
# Analysts2
Ownership
Shares Out.43.81M
Float22.71M
Insiders28.95%
Institutions3.61%
Technical
SMA 501.811 (-6.6%)
SMA 2002.754 (-38.6%)
Beta0.91
S&P 52W Chg12.00%
Avg Vol (30d)104.25K
Avg Vol (10d)119.53K
Technical Indicators
RSI (14)40.9
MACD-0.0130
MACD Signal-0.0113
MACD Hist.-0.0017
BB Upper1.881 USD
BB Middle1.768 USD
BB Lower1.655 USD
BB Width12.75%
ATR (14)0.0770 USD
Vol Ratio (20d)0.33x

About ABIONYX Pharma (EPA: ABNX)

›

ABIONYX Pharma (EPA: ABNX) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 49 employees.

The shares were at 1.542 EUR on 19 November 2026, down 63.2% over 52 weeks. Its 52-week range is 1.414 EUR to 4.400 EUR: the price is 65.0% below the high and 9.1% above the low.

Its market capitalisation is 68.78M EUR.

ABIONYX Pharma reports return on equity of -123.0%, an operating margin of -136.3% and revenue down 11.9% year over year.

Its debt exceeds its cash by 284.00K EUR, a debt-to-equity ratio of 0.84. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.